Danaher Corporation
NYSE:DHRMedical - Diagnostics & Research
-$0.38 today
- Market cap
- $160.69B
- Beta
- 0.83
- P/E (TTM)
- 34.0
- EPS (TTM)
- $5.21
- Dividend yield
- 0.77%
Volume 2.92M
Average 4.52M
DHR Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Danaher CorporationNYSE: DHR
Cost of Revenue · Q3 FY2026 · quarter ended Sep 2026
Cost of revenue grows, but more slowly than its trailing trend
Q3 FY2026 cost of revenue of $2.72B rose 7.4% year over year, behind the +12.9% change in trailing-twelve-month cost of revenue. Sequentially, it rose 2.4% from the prior quarter. Over 3 fiscal years it compounded at -2.8% a year.
Context
- Cost of revenue amounted to 39.1% of revenue in FY2025, down 1.4 pp from a year earlier.
- Cost of revenue increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +7.4% toward the trailing-twelve-month pace of +12.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 9.6B USD
- Year-over-year change
- -0.7%
- 4-year CAGR
- -4.4%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.6B | -0.7% |
| FY2024 | 2024-12-31 | 9.67B | -1.9% |
| FY2023 | 2023-12-31 | 9.86B | -5.7% |
| FY2022 | 2022-12-31 | 10.46B | -9.1% |
| FY2021 | 2021-12-31 | 11.5B | — |
Cost of Revenue vs competitors
How DHR compares with its peers on the latest reported figures
- DHR's LTM Sep 2026 cost of revenue of $10.6B is the 2nd highest of the 9 companies compared; the peer median is $1.79B.
- Its year-over-year change of +12.9% is the 2nd highest of 9, against a peer median of +6.7%.
- Cost of revenue amounts to 41.4% of revenue for DHR, versus a peer median of 47.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $27.73B | +6.5% | +0.5% | 58.6% | |
| LTM Sep 2026 | $10.6B | +12.9% | -2.8% | 41.4% | |
| LTM Jul 2026 | $3.41B | +6.8% | +1.9% | 46.3% | |
| LTM Jul 2026 | $2.29B | +83.1% | +2.3% | 49.2% | |
| LTM Jun 2026 | $1.87B | +4.7% | +14.9% | 53.3% | |
| LTM Jun 2026 | $1.72B | +7.4% | -0.8% | 41.6% | |
| LTM Jun 2026 | $1.49B | +6.0% | -3.6% | 33.2% | |
| LTM Jul 2026 | $1.39B | +8.5% | -4.8% | 47.9% | |
| LTM Jun 2026 | $801.85M | +6.1% | +1.8% | 38.2% | |
| Peer median (excluding DHR) | $1.79B | +6.7% | +1.2% | 47.1% | |
Competitors are the stored peer set for DHR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 29.45B | 26.64B | 23.89B | 23.88B | 24.57B |
| Cost of Revenue | 11.5B | 10.46B | 9.86B | 9.67B | 9.6B |
| Gross Profit | 17.95B | 16.19B | 14.03B | 14.21B | 14.97B |
| Gross Margin | 61.0% | 60.8% | 58.7% | 59.5% | 60.9% |
| Research & Development | 1.74B | 1.53B | 1.5B | 1.58B | 1.6B |
| Selling, General & Admin | 8.16B | 7.12B | 7.25B | 7.44B | 8.24B |
| Operating Expenses | 9.9B | 8.65B | 8.76B | 9.02B | 9.83B |
| Depreciation & Amortization | 2.17B | 2.13B | 2.17B | 2.35B | 2.45B |
| EBITDA | 10.01B | 9.49B | 7.5B | 7.28B | 6.95B |
| EBITDA Margin | 34.0% | 35.6% | 31.4% | 30.5% | 28.3% |
| Operating Income | 8.05B | 7.54B | 5.28B | 5.18B | 5.14B |
| Operating Margin | 27.3% | 28.3% | 22.1% | 21.7% | 20.9% |
| Interest Income | 11M | 41M | 303M | 117M | 30M |
| Interest Expense | 241M | 207M | 289M | 278M | 265M |
| Other Income / Expenses | (452M) | (390M) | (235M) | (538M) | (904M) |
| Income Before Tax | 7.6B | 7.15B | 5.04B | 4.65B | 4.23B |
| Pre-Tax Margin | 25.8% | 26.8% | 21.1% | 19.5% | 17.2% |
| Income Tax Expense | 1.25B | 818M | 823M | 747M | 619M |
| Net Income | 6.43B | 7.21B | 4.76B | 3.9B | 3.61B |
| Net Margin | 21.8% | 27.1% | 19.9% | 16.3% | 14.7% |
| EPS (Basic) | 8.77 | 9.80 | 6.44 | 5.33 | 5.07 |
| EPS (Diluted) | 8.61 | 9.64 | 6.38 | 5.29 | 5.04 |
| Weighted Avg Shares | 714.6M | 725.1M | 736.5M | 731M | 707.3M |
| Weighted Avg Shares (Diluted) | 736.8M | 737.1M | 743.1M | 737.2M | 711M |
Danaher Corporation
NYSE:DHR
Intrinsic Alpha fair value
Locked
Current Price
$228.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.